SCHEMBL471925

SCHEMBL471925

N[C@@H](Cc1c(O)[nH]c2ccccc12)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.55
MAPT P10636 3/20 0.55
LMNA P02545 2/20 0.55
TSHR P16473 2/20 0.55
BLM P54132 2/20 0.55
PMP22 Q01453 2/20 0.55
KMT2A Q03164 2/20 0.55
MEN1 O00255 1/20 0.55
MPO P05164 1/20 0.55
HIF1A Q16665 1/20 0.55
EGFR P00533 4/20 0.50
SRC P12931 2/20 0.50
SCN9A Q15858 1/20 0.50
SLC7A5 Q01650 2/20 0.49
ALPI P09923 1/20 0.49
PKM P14618 1/20 0.49
PTGS1 P23219 1/20 0.49
XIAP P98170 1/20 0.49
ALDH1A1 P00352 3/20 0.44
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL497627 1.00 KDM4E (0.55) KDM4EMAPTLMNATSHRBLM
SCHEMBL29415605 1.00 KDM4E (0.55) KDM4EMAPTLMNATSHRBLM
SCHEMBL6295317 1.00 KDM4E (0.55) KDM4EMAPTLMNATSHRBLM
Water SCHEMBL29189815 0.98 KDM4E (0.54) KDM4EMAPTLMNATSHRBLM
Sulfurous Acid SCHEMBL28577186 0.94 MAPT (0.50) KDM4EMAPTLMNATSHRBLM
Tryptophan SCHEMBL2721525 0.89 KMT2A (0.76) KDM4EMAPTLMNATSHRBLM
SCHEMBL27795130 0.88 SLC1A1 (0.55) KDM4EMAPTLMNATSHRBLM
SCHEMBL2263891 0.85 KDM4E (0.55) KDM4EMAPTLMNATSHRBLM
SCHEMBL7694812 0.85 KDM4E (0.55) KDM4EMAPTLMNATSHRBLM
SCHEMBL7694420 0.84 KDM4E (0.54) KDM4EMAPTLMNATSHRBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1878 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026099341-A1 BIOCONTAINMENT OF UNWANTED ENGINEERED CELLS USING NON-NATURAL AMINO ACIDS SNIPR BIOME APS (DK) 2026-05-15 WO claimed
CN-122017244-A Plasma metabolism marker for kidney cancer diagnosis and application thereof 哈尔滨脉图精准技术有限公司 2026-05-12 CN claimed
US-12600699-B2 Thiosemicarbazates and uses thereof THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2026-04-14 US claimed
US-12533325-B2 Composition and method for preventing or treating opioid withdrawal symptoms ANDRY JONATHAN B (US) 2026-01-27 US claimed
US-12415834-B2 GhR-binding peptide and composition comprising same PEPTIDREAM INC. (JP) 2025-09-16 US claimed
US-20250246314-A1 METHODS FOR THE DETECTION AND TREATMENT OF PANCREATIC DUCTAL ADENOCARCINOMA BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2025-07-31 US claimed
US-12351573-B2 Compounds for use in synthesis of peptidomimetics THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2025-07-08 US claimed
US-12329726-B2 Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-06-17 US claimed
CN-119736177-A Yeast engineering strain for synthesizing melatonin and construction method and application thereof 河南牧业经济学院 2025-04-01 CN claimed
WO-2025016307-A1 HEALTH HOMEOSTASIS MODEL, ELASTIC HOMEOSTASIS MODEL, AND USAGE METHOD THEREFOR 汤臣倍健股份有限公司 2025-01-23 WO claimed
US-20030113882-A1 Methods for the preparation of beta-amino acids WISCONSIN ALUMNI RESEARCH FOUNDATION 2003-06-19 US claimed
EP-0759299-B1 Potentiation of serotonin response LILLY CO ELI (US) 2000-04-26 EP claimed
US-5958429-A TREATING DEPRESSION ELI LILLY AND COMPANY (US) 1999-09-28 US claimed
WO-1997006792-A1 POTENTIATION OF SEROTONIN RESPONSE ELI LILLY AND COMPANY (US) 1997-02-27 WO claimed
EP-0759299-A1 Potentiation of serotonin response ELI LILLY AND COMPANY (US) 1997-02-26 EP claimed
US-5081225-A Novel antibiotic, janthinocin E. R. SQUIBB & SONS, INC. (US) 1992-01-14 US claimed
EP-0234186-B1 USE OF OLIGOPEPTIDS FOR THE TREATMENT OF CEREBRAL DISORDERS Fresenius AG (DE) 1991-11-06 EP claimed
EP-0234186-A1 Use of oligopeptids for the treatment of cerebral disorders Fresenius AG (DE) 1987-09-02 EP claimed
EP-0058111-B1 5-ACETYLOXY-L-TRYPTOPHANE AND ITS SALTS, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTICAL USES Laboratoires Merck-Clévenot (FR) 1985-10-23 EP claimed
US-4283337-A Process for the purification of tryptophane and derivatives of tryptophane DEUTSCHE GOLD UND- SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) 1981-08-11 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12351573-B2 Compounds for use in synthesis of peptidomimetics DNPEP, NPEPPS, PAM KDM4E 3819/4885MAPT 1350/4885LMNA 4762/4885
US-12415834-B2 GhR-binding peptide and composition comprising same GHRHR, GHSR, GIPR KDM4E 4589/4885MAPT 4092/4885LMNA 4434/4885
US-12533325-B2 Composition and method for preventing or treating opioid withdrawal symptoms S100B, SLC6A12, SLC6A13 KDM4E 2175/4885MAPT 302/4885LMNA 3102/4885
US-12600699-B2 Thiosemicarbazates and uses thereof MET, THRB, ABAT KDM4E 2649/4885MAPT 1679/4885LMNA 4184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.